Vorapaxar. PAR1 receptor antagonist, antiplatelet therapy

Drugs of the Future

Volumn 36, Issue 2, 2011, Pages 101-113

  Goto, S ^a   Serebruany, V ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; VORAPAXAR;

BLEEDING; DEBENZYLATION; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; FIBRINOLYTIC THERAPY; HUMAN; HYDROGENATION; KNOEVENAGEL CONDENSATION; LOADING DRUG DOSE; NONHUMAN; REVIEW;

EID: 84952982547     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.02.1514948     Document Type: Review

References (53)

1. Chackalamannil, S., Wang, Y., Greenlee, W.J. et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008, 51(11): 3061-4.
2. Chackalamannil, S., Greenlee, W.J., Xia, Y., Chelliah, M., Clasby, M.C., Wang, Y., Veltri, E.P. (Schering Corp.). Tricyclic thrombin receptor antagonists. EP 1495018, EP 1860106, EP 1982984, EP 2062890, EP 2065384, JP 2005528406, JP 2010132710, US 2003216437, US 7304078, WO 200308928.
3. Sudhakar, A., Kwok, D.-I., Wu, G.G., Green, M.D., Thiruvengadam, T.K., Lim, N.K., Wang, T., Huang, M. (Schering Corp.). An exo-selective synthesis of himbacine analogs. EP 1846385, JP 2008526974, US 2006217422, US 7772276, WO 2006076452.
4. Wu, G., Sudhakar, A.R., Wang, T. et al. (Schering Corp.). Exo- and diastereo- selective synthesis of himbacine analogs. CA 2594871, EP 1848705, EP 2196454, EP 2196468, EP 2206697, JP 2008526972, US 2006247450, WO 2006076415.
5. Clasby, M.C., Chackalamannil, S., Czarniecki, M. et al. Metabolism-based identification of a potent thrombin receptor antagonist. J Med Chem 2007, 50(1): 129-38.
6. Chackalamannil, S., Asberom, T., Xia, Y., Doller, D., Clasby, M.C., Czarniecki, M.F. Thrombin receptor antagonists. US 6063847.
7. Li, T., Tamarez, M.M., Zaks, A. (Schering Corp.). Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs. CA 2594742, EP 1848683, JP 2008526254, US 2006172397, WO 2006076565.
8. Thiruvengadam, T.K., Wang, T., Chiu, J.S., Liao, J. (Schering Corp.). Synthesis of 3-(5-nitrocyclohex-1-enyl)acrylic acid and esters thereof. EP 2035364, JP 2009542675, US 2008009651, WO 2008005344.
9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329): 71-86.
10. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994, 308(6921): 81-106.
11. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348(9038): 1329-39.
12. Baigent, C., Blackwell, L., Collins, R. et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373(9678):1849-60.
13. Toyoda, K., Yasaka, M., Iwade, K. et al. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective, multicenter, observational study. Stroke 2008, 39(6): 1740-5.
14. Goto, S. Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl 2005, 6(4): 3-11.
15. Yusuf, S., Zhao, F., Mehta, S.R., Chrolavicius, S., Tognoni, G., Fox, K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345(7):494-502.
16. Berger, P.B., Bhatt, D.L., Fuster, V. et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010, 121(23): 2575-83.
17. Wiviott, S.D., Braunwald, E., McCabe, C.H. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20): 2001-15.
18. Wang, T.Y., Xiao, L., Alexander, K.P. et al. Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 2008, 118(21): 2139-45.
19. Steg, P.G., Bhatt, D.L., Wilson, P.W. et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007, 297(11): 1197-206.
20. Bhatt, D.L., Eagle, K.A., Ohman, E.M. et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA 2010, 304(12): 1350-7.
21. Alberts, M.J., Bhatt, D.L., Mas, J.L. et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009, 30(19): 2318-26.
22. Bhatt, D.L., Steg, P.G., Ohman, E.M. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006, 295(2): 180-9.
23. Di Minno, G., Coppola, A., Di Minno, M.N., Poon, M.C. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): Proposals for management between evidence and open issues. Thromb Haemost 2009, 102(6): 1157-64.
24. Gurbel, P.A., Bliden, K.P., Guyer, K., Aggarwal, N., Tantry, U.S. Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: A new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. Thromb Res 2007, 119(5): 563-70.
25. Kastrati, A., Mehilli, J., Schuhlen, H. et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350(3): 232-8.
26. Nakagawa, Y., Nobuyoshi, M., Yamaguchi, T. et al. Efficacy of abciximab for patients undergoing balloon angioplasty: Data from Japanese evaluation of c7E3 Fab for elective and primary PCI organization in randomized trial (JEPPORT). Circ J 2009, 73(1): 145-51.
27. Jackson, S.P., Schoenwaelder, S.M. Antiplatelet therapy: In search of the 'magic bullet'. Nat Rev Drug Discov 2003, 2(10): 775-89.
28. Serebruany, V.L., Goto, S. The challenge of monitoring platelet response after clopidogrel. Eur Heart J 2008, 29(23): 2833-4.
29. Kawai, T., Yamagishi, T., Goto, S. Circadian variations of gastrointestinal mucosal damage detected with transnasal endoscopy in apparently healthy subjects treated with low-dose aspirin (ASA) for a short period. J Atheroscler Thromb 2009, 16(3): 155-63.
30. Hollopeter, G., Jantzen, H.M., Vincent, D. et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001, 409(6817): 202-7.
31. Hagihara, K., Kazui, M., Kurihara, A. et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos 2009, 37(11): 2145-52.
32. Wallentin, L., Becker, R.C., Budaj, A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-57.
33. Sano, K., Takai, Y., Yamanishi, J., Nishizuka, Y. A role of calcium-activated phospholipid-dependent protein kinase in human platelet activation. Comparison of thrombin and collagen actions. J Biol Chem 1983, 258(3):2010-3.
34. Kahn, M.L., Zheng, Y.W., Huang, W. et al. A dual thrombin receptor system for platelet activation. Nature 1998, 394(6694): 690-4.
35. De Marco, L., Mazzucato, M., Masotti, A., Ruggeri, Z.M. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem 1994, 269(9): 6478-84.
36. Coughlin, S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005, 3(8): 1800-14.
37. Sambrano, G.R., Weiss, E.J., Zheng, Y.W., Huang, W., Coughlin, S.R. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001, 413(6851): 74-8.
38. Tamura, N., Kitajima, I., Kawamura, Y., Toda, E., Eguchi, Y., Ishida, H., Goto, S. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J 2009, 73(3): 540-8.
39. Goto, S., Handa, S. Coronary thrombosis. Effects of blood flow on the mechanism of thrombus formation. Jpn Heart J 1998, 39(5): 579-96.
40. Connolly, A.J., Ishihara, H., Kahn, M.L., Farese, R.V. Jr., Coughlin, S.R. Role of the thrombin receptor in development and evidence for a second receptor. Nature 1996, 381(6582): 516-9.
41. Andersen, H., Greenberg, D.L., Fujikawa, K., Xu, W., Chung, D.W., Davie, E.W. Protease-activated receptor 1 is the primary mediator of thrombinstimulated platelet procoagulant activity. Proc Natl Acad Sci U S A 1999, 96(20): 11189-93.
42. Kahn, M.L., Nakanishi-Matsui, M., Shapiro, M.J., Ishihara, H., Coughlin, S.R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999, 103(6): 879-87.
43. Leger, A.J., Covic, L., Kuliopulos, A. Protease-activated receptors in cardiovascular diseases. Circulation 2006, 114(10): 1070-7.
44. Macaulay, T.E., Allen, C., Ziada, K.M. Thrombin receptor antagonism - The potential of antiplatelet medication SCH 530348. Expert Opin Pharmacother 2010, 11(6): 1015-22.
45. Angiolillo, D.J., Capodanno, D., Goto, S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010, 31(1): 17-28.
46. Doller, D., Chackalamannil, S., Czarniecki, M., McQuade, R., Ruperto, V. Design, synthesis, and structure-activity relationship studies of himbacine derived muscarinic receptor antagonists. Bioorg Med Chem Lett 1999, 9(6): 901-6.
47. Chackalamannil, S., Davies, R.J., Wang, Y. et al. Total synthesis of (+)-himbacine and (+)-himbeline. J Org Chem 1999, 64(6): 1932-40.
48. Tomasello, S.D., Angiolillo, D.J., Goto, S. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events. Expert Opin Investig Drugs 2010, 19(12): 1557-67.
49. Becker, R.C., Moliterno, D.J., Jennings, L.K. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet 2009, 373(9667): 919-28.
50. Goto, S., Yamaguchi, T., Ikeda, Y., Kato, K., Yamaguchi, H., Jensen, P. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb 2010, 17(2): 156-64.
51. Shinohara, Y., Goto, S., Doi, M., Jensen, P. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke. J Stroke Cerebrovasc Dis 2010, Epub ahead of print.
52. Morrow, D.A., Scirica, B.M., Fox, K.A. et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. Am Heart J 2009, 158(3): 335-41.
53. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: Study design and rationale. Am Heart J 2009, 158(3): 327-34.